Comparative efficacy and safety of Sofosbuvir/Velpatasvir and Danoprevir for the treatment of chronic hepatitis C: the real-world data in China

Table 2 Laboratory results between treatment protocol groups from baseline to follow-up

Parameters	ECS (n = 94)	DNV (n = 84)	All (n = 178)	P
Baseline
ALT^a, U/L	82.54 ± 75.39	73.48 ± 54.65	78.04 ± 65.82	0.406
AST^b, U/L	66.57 ± 45.63	60.44 ± 42.54	63.53 ± 44.08	0.401
WBC^c	6.37 ± 1.60	6.35 ± 1.87	6.16 ± 1.96	0.177
Hb^d	144.28 ± 20.49	144.28 ± 20.49	137.40 ± 29.72	0.101
PLT^e	154.06 ± 75.00	176.78 ± 66.93	165.01 ± 71.88	0.062
4-week treatment
ALT, U/L	30.51 ± 20.25	22.28 ± 10.51	26.28 ± 16.47	0.007
AST, U/L	33.13 ± 14.78	23.58 ± 7.63	28.23 ± 12.56	< 0.001
WBC	5.65 ± 2.11	6.10 ± 1.22	5.77 ± 1.92	0.416
Hb	134.53 ± 21.09	137.08 ± 17.19	135.62 ± 19.45	0.544
PLT	161.82 ± 73.85	173.00 ± 68.94	166.60 ± 71.61	0.470
12-week treatment
ALT, U/L	27.29 ± 21.76	23.58 ± 10.28	26.49 ± 18.32	0.209
AST, U/L	31.92 ± 20.39	24.31 ± 8.82	29.01 ± 17.27	0.030
WBC	6.02 ± 1.81	5.58 ± 1.77	5.86 ± 1.80	0.271
Hb	136.38 ± 24.63	136.00 ± 18.69	136.33 ± 23.92	0.969
PLT	162.23 ± 73.57	199.75 ± 62.68	175.87 ± 71.77	0.029
12-week follow-up
ALT, U/L	26.38 ± 7.38	17.24 ± 3.90	23.88 ± 7.76	< 0.001
AST, U/L	26.38 ± 7.38	17.24 ± 3.90	23.88 ± 7.76	< 0.001
WBC	6.32 ± 2.12	6.58 ± 0.983	6.36 ± 1.80	0.748
Hb	140.59 ± 19.19	136.00 ± 18.69	139.86 ± 18.97	0.563
PLT	171.54 ± 57.25	252.14 ± 56.84	184.36 ± 63.91	0.001

ISSN: 1471-230X